PGN36

Overview

PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with K i s of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD).

Application

Products | Products > Disease Areas > Obesity | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pain | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Cannabinoid Receptor

Product Information

• Catalog No.: HY-146134
• CAS No.: 1564253-75-3
• Molecular Formula: C21H23N3O3
• Molecular Weight: 365.43
• Purity: 99.59%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source